Tonix Pharmaceuticals to Present at the 2018 BIO International Convention
May 30, 2018 08:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will...
Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL
May 24, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 24, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced preliminary results from a Phase 1 pivotal multiple-dose bridging pharmacokinetic...
Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology
May 23, 2018 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 23, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix) announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix, will present at the...
Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update
May 14, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Interim Analysis for Phase 3 HONOR study of Tonmya® in Military-Related PTSDExpected in Third Quarter of 2018 NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp....
Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention
May 07, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 07, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to...
Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease
May 01, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational...
Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York
April 04, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
First 50 Percent of Participants Enrolled in Phase 3 HONOR Study of Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of Military-Related PTSD Interim Results of HONOR Study Expected...
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
April 03, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Phase 3 HONOR Study Enrollment Continues and Interim Results of the First 50 Percent of Participants Expected in Third Quarter 2018 Topline Results of Approximately 550 Participants with...
Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL
March 21, 2018 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
U.S. Patent Issued Covering the Use of Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for treating Posttraumatic Stress Disorder (PTSD) Patent Will Provide Intellectual Property Protection until at...
Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
March 13, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that it will present at the B. Riley FBR Inaugural China Healthcare Investing...